
A study published in the European Respiratory Journal suggests that in addition to elevated blood eosinophil counts, baseline clinical factors can help identify patients who would potentially be responsive to benralizumab (Fasenra), among patients with severe, uncontrolled asthma with eosinophilic inflammation.